Debut Plus

₹1,404.3

▼ -37.19 -2.58%

As of 23 Oct 2026 · delayed

NSE Listed

LT-ASM · ASM 4
What does LT-ASM · ASM 4 mean?
BSE · Long Term Additional Surveillance Measure (ASM 4)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-06-11
NSE · Long Term Additional Surveillance Measure (ASM 4)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

Venus Remedies Limited (VENUSREM)

Volume: 52,800Avg Vol 1W: 40,268.4Avg Vol 1M: 35,048.7552W Range:₹432.1₹2,044.3
Market Cap₹1,877 Cr
Current Price₹1,404.3
Previous Close₹1,441.49
High / Low (52w)₹2,044.3 / ₹432.1
Volume52,800
Avg Vol (1W)40,268.4
Avg Vol (1M)35,048.75
Stock P/E16.16
Book Value₹496.56
Dividend Yield72%
ROE15.49%
ROA13.61%
Revenue (TTM)₹669 Cr
Revenue Growth7.7%
Profit Margin14.32%
Total Debt₹0 Cr
Shares Outstanding1 Cr
Face Value₹10
EPS (TTM)₹86.92
P/B2.81
Debt / Equity0.01
50 DMA₹1,650.51
200 DMA₹1,300.83
Day change-2.58%
SurveillanceLT-ASM · ASM 4
Price Chart
₹1,404.3▲ 220.76% · 1Y
₹1947₹4348.8L
2025-10-27
2026-10-23

20-day avg volume: 35K shares

Pros
  • Healthy return on equity of 15.5%.
  • Pays a dividend yield of 72.0%.
  • Company is almost debt-free.
  • Revenue grew 14% YoY.
Cons
  • Company is loss-making at the latest annual result.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹170 Cr₹177 Cr₹195 Cr₹137 Cr₹193 Cr₹180 Cr₹259 Cr₹179 Cr
EBITDA₹9 Cr₹15 Cr₹31 Cr₹13 Cr₹27 Cr₹33 Cr₹62 Cr₹30 Cr
Net Profit₹4 Cr₹20 Cr₹21 Cr₹10 Cr₹20 Cr₹26 Cr₹48 Cr₹23 Cr
EPS————————
Profit & Loss (Annual)
MetricDec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹172 Cr₹669 Cr₹197 Cr₹137 Cr₹193 Cr₹180 Cr₹259 Cr₹179 Cr
EBITDA₹19 Cr₹62 Cr₹25 Cr₹15 Cr₹26 Cr₹33 Cr₹58 Cr₹33 Cr
Net Profit₹24 Cr₹45 Cr₹15 Cr₹12 Cr₹19 Cr₹25 Cr₹43 Cr₹26 Cr
EPS—33.9——————
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹751 Cr₹733 Cr₹644 Cr₹556 Cr₹580 Cr₹601 Cr₹627 Cr₹716 Cr
Total Liabilities₹389 Cr₹400 Cr₹320 Cr₹156 Cr₹139 Cr₹141 Cr₹139 Cr₹155 Cr
Equity₹362 Cr₹333 Cr₹323 Cr₹400 Cr₹440 Cr₹460 Cr₹488 Cr₹561 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹45 Cr₹63 Cr₹108 Cr₹41 Cr₹37 Cr₹53 Cr₹101 Cr₹190 Cr
Investing₹-11 Cr₹-5 Cr₹56 Cr₹-17 Cr₹-51 Cr₹-7 Cr₹-76 Cr₹-182 Cr
Financing₹-35 Cr₹-73 Cr₹-162 Cr₹-9 Cr₹-1 Cr₹-1 Cr₹-1 Cr₹-3 Cr
Free Cash Flow₹45 Cr₹63 Cr₹108 Cr₹41 Cr₹37 Cr₹53 Cr₹101 Cr₹190 Cr
Shareholding
Promoter 41.76% Institutions 3.88% Public 54.36%
Efficiency & Working Capital
ROCE19.8%
Interest Coverage3354.8
Dividend Payout—
Debtor Days49 d
Inventory Days61 d
Payable Days54 d
Cash Conversion Cycle57 d
Working Capital Days110 d
Shareholding Details

As of 2026-09-30

Promoter41.8%
FII3.1%
DII0.7%
Institutions3.9%
Public54.4%
Promoter Pledge0%
No. of Shareholders22,968
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Promoters41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%
FIIs1.6%1.5%1.1%1.2%1.1%1.3%2.2%1.9%2.3%2.8%2.9%3.1%
DIIs0.1%0.1%0.1%0.1%0%0%0.1%0.7%1%1.2%0.9%0.7%
Public56.5%56.6%57%56.9%57.1%56.9%55.9%55.6%55%54.2%54.4%54.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders19,56019,91319,61419,55719,77119,98219,30717,72518,60618,40321,90522,968
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Sunev Pharma Solutions Pvt LtdShareholding of Promoter and Promoter Group17.2%23,00,000
Pawan ChaudharyShareholding of Promoter and Promoter Group12.8%17,13,946
Manu ChaudharyShareholding of Promoter and Promoter Group11.7%15,68,000
Tikri Partners LlpPublic Shareholding2%2,62,700
Rajni Tarun JainPublic Shareholding1.4%1,90,000
Acadian Emerging Markets Micro-cap Equity Master FundPublic Shareholding1.1%1,47,501
Nisarg Ajaykumar VakhariaPublic Shareholding1.1%1,40,000
Investor Education And Protection Fund Authority Ministry Of Corporate AffairsPublic Shareholding1%1,33,741
Spine Software Systems Pvt LtShareholding of Promoter and Promoter Group0%0
Tark Ai Pvt LtdShareholding of Promoter and Promoter Group0%0
Radha Luxmi InvestmentsShareholding of Promoter and Promoter Group0%0
Plea Charitable TrustShareholding of Promoter and Promoter Group0%0
Venus Foundation TrustShareholding of Promoter and Promoter Group0%0
Peeyush JainShareholding of Promoter and Promoter Group0%50
Akshansh ChaudharyShareholding of Promoter and Promoter Group0%1
Ashutosh JainShareholding of Promoter and Promoter Group0%0
Saransh ChaudharyShareholding of Promoter and Promoter Group0%0
Aditi K ChaudharyShareholding of Promoter and Promoter Group0%0
Ekta ThakurShareholding of Promoter and Promoter Group0%0
Monica JainShareholding of Promoter and Promoter Group0%0
Alka JainShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Pawan ChaudharyChairman / WTD / Managing Director / CFO2025
Manu ChaudharyWhole Time Director & JMD2025
Peeyush JainWhole Time Director / Deputy Managing Director2025
Ashutosh JainE D & Wholetime Director2025
Akshansh ChaudharyWhole Time Director & CTO2025
Navdeep SudIndependent Director2025
Savita GuptaIndependent Director2025
Pravindra Singh ChauhanIndependent Non Exe. Director2025
Nps MongaIndependent Non Exe. Director2025
Anil KumarIndependent Non Exe. Director2025
Jagdish Chander SharmaIndependent Non Exe. Director2025
Neha AroraCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Pharmaceutical Formulation₹0 Cr—
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10201313
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-07Dividend (10/- per share)Final
dividend2026-08-07₹10 (100%)Final
forthcoming2026-07-20Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202625000142
2026000004
20260000113
Insider / Designated-Person Trades

3 recent disclosure(s)

PAWAN CHAUDHARYAcquisition · 1,26,946
PAWAN CHAUDHARY RevisedAcquisition · 6,00,000
MANU CHAUDHARY RevisedAcquisition · 4,25,000
Company Information
Incorporated1989
ChairmanPawan Chaudhary
AuditorJ K Jain & Associates
Investor Email[email protected]; complianceoff
🌐 www.venusremedies.com ↗

📍 S C No 857 Cabin No 10 2nd Flr, N A C Manimajra, Chandigarh, Chandigarh, 160101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search